{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:50:50Z","timestamp":1784969450283,"version":"3.55.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-01906-x","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:02:07Z","timestamp":1711008127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials"],"prefix":"10.1093","author":[{"given":"I. Kitty","family":"Stanley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton M.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Viecelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8752-2551","authenticated-orcid":false,"given":"Andrew J.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"issue":"1","key":"1906_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt K et al (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88(1):17\u201327. https:\/\/doi.org\/10.1038\/ki.2015.59","journal-title":"Kidney Int"},{"issue":"11","key":"1906_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10157-019-01770-1","volume":"23","author":"I Capuano","year":"2019","unstructured":"Capuano I, Riccio E, Caccavallo S et al (2019) ADPKD and metformin: from bench to bedside. Clin Exp Nephrol 23(11):1341\u20131342. https:\/\/doi.org\/10.1007\/s10157-019-01770-1","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"1906_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","volume":"100","author":"RD Perrone","year":"2021","unstructured":"Perrone RD, Abebe KZ, Watnick TJ et al (2021) Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int 100(3):684\u2013696. https:\/\/doi.org\/10.1016\/j.kint.2021.06.013","journal-title":"Kidney Int"},{"issue":"4","key":"1906_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","volume":"79","author":"GM Brosnahan","year":"2022","unstructured":"Brosnahan GM, Wang W, Gitomer B et al (2022) Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study. Am J Kidney Dis 79(4):518\u2013526. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.026","journal-title":"Am J Kidney Dis"},{"key":"1906_CR5","unstructured":"ClinicalTrials.gov. Identifier: NCT04939935, Implementation of metformin therapy to ease decline of kidney function in polycystic kidney disease (IMPEDE-PKD). 2022 [28\/11\/2022]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04939935."},{"issue":"25","key":"1906_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418. https:\/\/doi.org\/10.1056\/NEJMoa1205511","journal-title":"N Engl J Med"},{"issue":"20","key":"1906_CR7","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O et al (2017) Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377(20):1930\u20131942. https:\/\/doi.org\/10.1056\/NEJMoa1710030","journal-title":"N Engl J Med"},{"key":"1906_CR8","unstructured":"ClinicalTrials.gov. Identifier: NCT03764605. Metformin vs Tolvaptan for treatment of autosomal dominant polycystic kidney disease (METROPOLIS). 2018 [29\/11\/2022]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03764605."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-01906-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-01906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:05Z","timestamp":1777564445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/5\/1417\/8307158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":8,"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-01906-x","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AMP is an employee of Otsuka Pharmaceutical Development & Commercialization. AJM is supported by a Queensland Health Advancing Clinical Research Fellowship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board or ethics committee at each site for the TEMPO 3:4 [NCT00428948] and REPRISE [NCT02160145] clinical trials provided ethical approval for each trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The TEMPO 3:4 [NCT00428948] and REPRISE [NCT02160145] clinical trials were carried out in accordance with and adhered to all relevant human rights and research guidelines and regulations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"All participants in both the TEMPO 3:4 [NCT00428948] and REPRISE [NCT02160145] clinical trials provided written informed consent for participation, data collection and analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}